Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations
Clinical Gastroenterology and Hepatology · 2024-07 · 22 (7) · 1373-1376
DOI: 10.1016/j.cgh.2024.01.042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-07. Verfasst von Amrit K Kamboj und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: Amrit.Kamboj@cshs.org. Hauptthemen laut MEDLINE: Proton Pump Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Take-Home Message Although PPI use is common, only a few conditions warrant its long-term use including severe erosive esophagitis, peptic stricture, BE, conclusive nonerosive GERD with ongoing symptoms responsive to PPI, PPI-responsive EoE, other chronic esophageal mucosal diseases, peptic ulcer disease with nonmodifiable risk factor, prevention of bleeding in high-risk patients, and hypersecretory conditions. When required long-term, efforts should be made to use the lowest possible dosing necessary to manage patient symptoms and underlying condition. In patients that do not meet indication for long-term PPIs, efforts should be made to deprescribe these medications. Although PPIs are often linked to various adverse conditions, these potential associations are largely based on low-quality studies with inherent limitations and do not establish definite causation. Multiple larger-scale studies have also demonstrated contrary results showing no such associations besides a marginal increase in enteric infections. Additionally, given that the absolute risk of these adverse events is overall low, the contribution of PPIs in further increasing these risks is modest at best, especially when used low-dose once daily. In general, routine testing should not be performed in those on long-term PPIs unless risk factors for specific conditions exist. In carefully selected patients with an appropriate indication, the gastroenterology community agrees that the benefits of long-term PPI use substantially outweigh the potential risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: Amrit.Kamboj@cshs.org.
- Division of Gastroenterology and Hepatology, Vanderbilt University, Nashville, Tennessee.
- Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, California.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Kamboj, A. K., Patel, D. A., & Yadlapati, R. (2024). Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations. Clinical Gastroenterology and Hepatology, 22(7), 1373-1376. https://doi.org/10.1016/j.cgh.2024.01.042
Vancouver
Kamboj AK, Patel DA, Yadlapati R. Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations. Clinical Gastroenterology and Hepatology. 2024;22(7):1373-1376. doi:10.1016/j.cgh.2024.01.042
BibTeX
@article{Kamboj2024,
author = {Kamboj, Amrit K and Patel, Dhyanesh A and Yadlapati, Rena},
title = {Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
volume = {22},
number = {7},
pages = {1373--1376},
doi = {10.1016/j.cgh.2024.01.042}
}
EUVIMED